Patent · US Active

Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl} pyrimidine-2,4-diamine

US11427605B2 · kind B2 · utility

0Cited by

4References

8Claims

0Family size

Assignee

Takeda Pharmaceutical Company Limited · JP

Inventors

Leonard W. Rozamus · Andover, US
Pradeep Sharma · Westford, US

Key dates

Filing date	Dec 16, 2020
Grant date	Aug 30, 2022
Priority date	—
Expiry date	Dec 16, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Novel crystalline forms of brigatinib, pharmaceutical compositions comprising the same, and methods of their preparation and use of the same are disclosed herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.